You are currently browsing the archives for November 2017.
Displaying 43 - 48 of 48 entries.

AskBio enters patent permit agreement with Pfizer for HCV therapy Asklepios BioPharmaceutical.

HCV infection may be the most common chronic blood-borne an infection in the usa, with approximately 3. 2 million people chronically contaminated. ‘This license represents another example of AskBio‘s progress in the advancement and commercialization of gene-delivery platform technology that focuses on creating worth for a broad range of therapeutic options for patients, including those with HCV.’.. AskBio enters patent permit agreement with Pfizer for HCV therapy Asklepios BioPharmaceutical, Inc. , a privately-owned clinical-stage biotechnology company, announced today it offers entered right into a patent permit agreement with Pfizer, Inc.

Bionovo initiates enrollment in Menerba Stage 1 scientific trial for menopausal hot flushes Bionovo.

Wulf Utian will serve while the Principal Investigator because of this scholarly study. Related StoriesMD Anderson research reveals why chemotherapy medications not effective for most pancreatic cancer patientsCrucial modification in single DNA bottom predisposes children to intense form of cancerMeat-rich diet plan may increase kidney tumor risk We are very happy to announce that people are initiating the Stage 1 tolerability medical trial. We are self-confident that the trial will proceed quickly and effectively.

A company centered on treatments and diagnostics for misfolded proteins diseases.

Amorfix Life Sciences indicators sale and distribution contract with Cedarlane Laboratories Amorfix Life Sciences, a company centered on treatments and diagnostics for misfolded proteins diseases, announced today that it has signed an agreement with Cedarlane Laboratories for the sale and distribution of Amorfix’s proprietary antibodies and reagents. Amorfix has developed the world’s most sensitive diagnostic assays for variant Creutzfeldt-Jakob Disease and for aggregated Abeta, the sign of Alzheimer’s Disease . Consequently, we’ve received several inquiries from investigators involved with protein misfolding studies for our reagents, said Dr haldol depot . George Adams, CEO of Amorfix.

Gingivalis associated with its virulence.

Finding a highly effective treatment for smokers contaminated with P. Gingivalis will end up being easier given that these changes in the bacterium’s ‘properties’ have been identified. University of Louisville researcher, Dr David Scott stated: ‘It has long been known that smokers are even more vunerable to periodontitis than are non-smokers. However, the reasons why are not so clear. Our study shows, for the first time, that components in cigarette smoke alter key characteristics of a major bacterial pathogen which, subsequently, changes how our immune system reacts to it. It could turn out that people need to develop alternate treatment programs for smokers and nonsmokers’..

Diarrhoea with antibiotics can promote the pass on of drug-resistant super-bacteria.

Antibiotic use by travellers may promote spread of drug-resistant ‘super-bacteria’ Dealing with travellers' diarrhoea with antibiotics can promote the pass on of drug-resistant super-bacteria . Each full year, more than 300 million tourists visit with low standards of hygiene areas. A recently available Finnish study shows that about one-fifth of the travellers return home with an undesired companion, a drug-resistant intestinal bacterium. The chance of being contaminated with a drug-resistant intestinal bacterium raises significantly if the traveller evolves diarrhoea and particularly if he or she uses antibiotics to treat it, says Docent Anu Kantele of Helsinki University Central Hospital, an infectious disease expert who led the scholarly research published in the journal Clinical Infectious Diseases.

2007 and updated earnings assistance for the full year.

Bristol-Myers Squibb Company Reports Financial Results Bristol-Myers Squibb Business reported financial results for the 3rd quarter and nine a few months ended September 30, 2007 and updated earnings assistance for the full year. The business posted third quarter 2007 net sales of $5.1 billion, a rise of 22 percent over the same period in 2006 avodart generic . Bristol-Myers Squibb reported third one fourth 2007 net earnings of $858 million, or $0.43 per diluted share, under U.S. Generally Recognized Accounting Principles , in comparison to $338 million, or $0.17 per diluted talk about for the same period in 2006. The 2007 results add a one-time pre-taxes gain of $247 million ($144 million net of taxes, or $0.